Silver Book

Silver Book Fact

Global use of vaccine prevents death

Compared to estimated deaths without vaccination, global use of vaccination in 2001 prevented: 61% of measles deaths; 69% of tetanus deaths; 78% of pertussis (whooping cough) deaths; 94% of diphtheria deaths; and 98% of polio deaths.

Brenzel, Logan, Lara J. Wolfson, Julia Fox-Rushby, Mark Miller, and Neal A. Halsey. Vaccine-Preventable Diseases In: Disease Control Priorities in Developing Countries (Second Edition). Disease Control in Developing Countries. 2006; 389-412. http://elibrary.worldbank.org/doi/pdf/10.1596/978-0-8213-6179-5

Reference

Title
Vaccine-Preventable Diseases In: Disease Control Priorities in Developing Countries (Second Edition)
Publication
Disease Control in Developing Countries
Publisher
Oxford University Press and The World Bank
Publication Date
2006
Authors
Brenzel, Logan, Lara J. Wolfson, Julia Fox-Rushby, Mark Miller, and Neal A. Halsey
Pages
389-412
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Shingles vaccine would reduce healthcare use
    Use of the shingles vaccine in immunocompetent adults could eliminate more than 300,000 outpatient visits, 375,000 prescriptions, 9,700 emergency room visits, and 10,000 hospitalizations.  
  • Potential value of pneumonia vaccine
    Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4…  
  • Use of shingles vaccine could save $82 to $103 million
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
  • Each flu case prevented could save $60 to $4,000
    The influenza vaccination could save between $60 and $4,000 per case prevented.  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.